NDC 13533-810-20 Xembify

Immune Globulin Subcutaneous, Human-klhw

  1. Labeler Index
  2. Grifols Usa, Llc
  3. 13533-810
  4. NDC Code: 13533-810-20 Xembify

NDC Package Code 13533-810-20

The NDC Code 13533-810-20 is assigned to a package of 1 vial in 1 carton > 20 ml in 1 vial (13533-810-21) of Xembify, a plasma derivative labeled by Grifols Usa, Llc. The product's dosage form is solution and is administered via subcutaneous form.

Field Name Field Value
NDC Code 13533-810-20
Package Description 1 VIAL in 1 CARTON > 20 mL in 1 VIAL (13533-810-21)
Proprietary Name Xembify What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Immune Globulin Subcutaneous, Human-klhw What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format 13533081020 NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type Plasma Derivative What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name Grifols Usa, Llc
Dosage Form Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route(s)
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
  • HUMAN IMMUNOGLOBULIN G 200 mg/mL
Pharmacological Class(es)
  • Human Immunoglobulin G - [EPC] (Established Pharmacologic Class)
  • Passively Acquired Immunity - [PE] (Physiologic Effect)
  • Antigen Neutralization - [MoA] (Mechanism of Action)
  • Immunoglobulins - [CS]
Sample Package No Sample Package?
This field Indicates whether this package is a sample packaging or not.
Marketing Category BLA - A product marketed under an approved Biologic License Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number BLA125683 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date 07-03-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

NDC Code Structure

  • 13533 - Grifols Usa, Llc
    • 13533-810 - Xembify
      • 13533-810-20 - 1 VIAL in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 13533-810-20 HCPCS crosswalk information with package details and bill units information.

NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
13533081020J1558Inj. xembify, 100 mg100 MG2014040

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Xembify with product NDC 13533-810.

NDC Package CodePackage Description
13533-810-051 VIAL in 1 CARTON > 5 mL in 1 VIAL (13533-810-06)
13533-810-101 VIAL in 1 CARTON > 10 mL in 1 VIAL (13533-810-11)
13533-810-501 VIAL in 1 CARTON > 50 mL in 1 VIAL (13533-810-51)

* Please review the disclaimer below.